ADC Therapeutics SA ADCT:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
4.90UNCH (UNCH)
Volume
770
Close
4.90quote price arrow up+0.17 (+3.59%)
Volume
321,903
52 week range
0.36 - 6.04
Loading...
  • Open4.96
  • Day High5.11
  • Day Low4.81
  • Prev Close4.73
  • 52 Week High6.04
  • 52 Week High Date02/20/24
  • 52 Week Low0.36
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap405.789M
  • Shares Out82.81M
  • 10 Day Average Volume0.33M
  • Dividend-
  • Dividend Yield-
  • Beta1.69
  • YTD % Change195.18

KEY STATS

  • Open4.96
  • Day High5.11
  • Day Low4.81
  • Prev Close4.73
  • 52 Week High6.04
  • 52 Week High Date02/20/24
  • 52 Week Low0.36
  • 52 Week Low Date11/13/23
  • Market Cap405.789M
  • Shares Out82.81M
  • 10 Day Average Volume0.33M
  • Dividend-
  • Dividend Yield-
  • Beta1.69
  • YTD % Change195.18

RATIOS/PROFITABILITY

  • EPS (TTM)-2.93
  • P/E (TTM)-1.67
  • Fwd P/E (NTM)-2.28
  • EBITDA (TTM)-164.799M
  • ROE (TTM)-705.53%
  • Revenue (TTM)69.558M
  • Gross Margin (TTM)96.36%
  • Net Margin (TTM)-337.16%
  • Debt To Equity (MRQ)-280.81%

EVENTS

  • Earnings Date05/06/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On ADC Therapeutics SA

 

Profile

MORE
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first...
Michael Forer
Vice Chairman of the Board
Ron Squarer
Non-Executive Chairman of the Board
Ameet Mallik
Chief Executive Officer, Director
Jose Carmona
Chief Financial Officer
Address
Biopole, route de la Corniche 3B
Epalinges
1066
Switzerland

Top Peers

SYMBOLLASTCHG%CHG
ENTA
Enanta Pharmaceuticals Inc
15.17+1.26+9.06%
FATE
Fate Therapeutics Inc
4.06-0.04-0.98%
EDIT
Editas Medicine Inc
5.67+0.05+0.89%
TBPH
Theravance Biopharma Inc
9.46+0.09+0.96%
MRSN
Mersana Therapeutics Inc
3.46+0.10+2.98%